骨髓瘤自体干细胞移植：圣詹姆斯医院的经验，1997 - 2003年
Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003.
作者信息
Hayden P J, O'Driscoll A, Gardiner N, Swords R, Sargent J, Ni Ainle F, Fortune A, Murphy P T, Leahy M, Jackson F, Ryan M, Hennessy B, Cahill M, Crotty G M, Enright H, Conneally E, Vandenberghe E, McCann S R, Browne P V
机构信息
Dept. of Haematology, St James's Hospital, Dublin 8, Ireland.
出版信息
Ir J Med Sci. 2005 Apr-Jun;174(2):26-32. doi: 10.1007/BF03169125.
BACKGROUND
High-dose treatment with autologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years.
AIMS
We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive.
METHODS
Clinical and laboratory data were retrieved from patient medical records and hospital information management systems.
RESULTS
Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n = 54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively.
CONCLUSION
Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.
背景
高剂量自体干细胞移植（ASCT）治疗已成为65岁以下骨髓瘤患者的标准治疗方案。
目的
我们报告了对1997年至2003年（含）期间在都柏林圣詹姆斯医院国家骨髓移植中心接受ASCT的60例患者（中位年龄：52.5岁）的一项审核。
方法
从患者病历和医院信息管理系统中检索临床和实验室数据。
结果
36例患者为IgG型，11例为IgA型，1例为IgD型，9例为轻链型，3例为非分泌型骨髓瘤。57例（95%）患者在自体移植前接受了蒽环类药物-皮质类固醇联合化疗。无移植相关死亡率（TRM）。在可评估的患者中（n = 54，占90%），16例（29.6%）达到完全缓解（CR），29例（53.7%）达到部分缓解（PR）。五年时的无进展生存（PFS）率和总生存（OS）率分别为13%和55%。
结论
该中心的治疗结果与已发表的国际系列研究相当，支持将ASCT用于治疗这种恶性肿瘤。
Zotero 插件